vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $3.9M, roughly 1.1× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -52.5%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -57.6%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
CWD vs IRD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $3.9M |
| Net Profit | $-7.7M | — |
| Gross Margin | — | — |
| Operating Margin | -196.6% | — |
| Net Margin | -188.3% | — |
| Revenue YoY | -52.5% | -10.2% |
| Net Profit YoY | 32.2% | 53.0% |
| EPS (diluted) | $1.95 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $3.9M | ||
| Q3 25 | $3.6M | $3.1M | ||
| Q2 25 | $5.1M | $2.9M | ||
| Q1 25 | $7.3M | $4.4M | ||
| Q4 24 | $8.7M | $4.3M | ||
| Q3 24 | $11.3M | $3.9M | ||
| Q2 24 | $8.2M | $1.1M | ||
| Q1 24 | $23.0M | $1.7M |
| Q4 25 | $-7.7M | — | ||
| Q3 25 | $-4.4M | $-17.5M | ||
| Q2 25 | $-5.3M | $-7.4M | ||
| Q1 25 | $-4.4M | $-8.2M | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $146.0K | $-7.5M | ||
| Q2 24 | $-4.7M | $-7.8M | ||
| Q1 24 | $-3.8M | $-7.1M |
| Q4 25 | -196.6% | — | ||
| Q3 25 | -129.6% | -269.9% | ||
| Q2 25 | -112.4% | -309.0% | ||
| Q1 25 | -62.7% | -227.2% | ||
| Q4 24 | -236.8% | — | ||
| Q3 24 | 0.0% | -207.1% | ||
| Q2 24 | -65.0% | -748.9% | ||
| Q1 24 | -22.9% | -450.5% |
| Q4 25 | -188.3% | — | ||
| Q3 25 | -120.2% | -566.9% | ||
| Q2 25 | -104.5% | -257.5% | ||
| Q1 25 | -60.7% | -187.5% | ||
| Q4 24 | -247.6% | — | ||
| Q3 24 | 1.3% | -194.6% | ||
| Q2 24 | -57.8% | -698.3% | ||
| Q1 24 | -16.6% | -415.3% |
| Q4 25 | $1.95 | — | ||
| Q3 25 | $-1.65 | $-0.25 | ||
| Q2 25 | $-4.15 | $-0.12 | ||
| Q1 25 | $-3.85 | $-0.24 | ||
| Q4 24 | $-10.15 | — | ||
| Q3 24 | $0.12 | $-0.29 | ||
| Q2 24 | $-4.34 | $-0.30 | ||
| Q1 24 | $-3.53 | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $45.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3M | $15.3M |
| Total Assets | $135.4M | $50.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $45.1M | ||
| Q3 25 | $10.9M | $30.8M | ||
| Q2 25 | $683.0K | $32.4M | ||
| Q1 25 | $1.6M | $41.8M | ||
| Q4 24 | $2.3M | $30.3M | ||
| Q3 24 | $1.6M | $36.6M | ||
| Q2 24 | $1.8M | $41.4M | ||
| Q1 24 | $2.1M | $47.2M |
| Q4 25 | $1.3M | $15.3M | ||
| Q3 25 | $4.2M | $6.0M | ||
| Q2 25 | $-19.9M | $17.5M | ||
| Q1 25 | $-15.8M | $5.1M | ||
| Q4 24 | $-12.6M | $6.7M | ||
| Q3 24 | $-3.8M | $34.3M | ||
| Q2 24 | $-4.7M | $40.6M | ||
| Q1 24 | $-745.0K | $46.1M |
| Q4 25 | $135.4M | $50.2M | ||
| Q3 25 | $82.6M | $36.1M | ||
| Q2 25 | $59.3M | $38.7M | ||
| Q1 25 | $103.6M | $48.2M | ||
| Q4 24 | $105.5M | $36.9M | ||
| Q3 24 | $158.6M | $40.4M | ||
| Q2 24 | $195.2M | $44.8M | ||
| Q1 24 | $201.5M | $51.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-35.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-35.3M | ||
| Q3 25 | $-4.6M | $-6.2M | ||
| Q2 25 | $-1.2M | $-10.3M | ||
| Q1 25 | $-1.7M | $-9.0M | ||
| Q4 24 | $555.0K | $-25.6M | ||
| Q3 24 | $-74.0K | $-5.1M | ||
| Q2 24 | $1.4M | $-7.3M | ||
| Q1 24 | $-1.5M | $-5.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
